On March 15, 2021, Boyarski et al.
Personalized Medicine For Better Health
19, Mar 2021
5, Jan 2021
31, Dec 2020
Recurring symptoms lasting several months may require ongoing treatment in some patients who have experienced COVID-1
29, Dec 2020
A new variant of the coronavirus that causes COVID-19 has been reported in the UK.
4, Dec 2020
24, Nov 2020
Kidney transplant patients are vulnerable to severe COVID-19 infection due to chronic immunosuppression and underlyin
18, Nov 2020
Healthcare Workers at Significant COVID-19 Risk
19, Oct 2020
Plexision has been awarded a National Science Foundation (NSF) Phase 1 Small Business Innovation Research Grant.
11, Sep 2014
PITTSBURGH, Sept. 11, 2014 /PRNewswire-iReach/ -- Today the FDA announced approval of PleximmuneTM
27, Nov 2013
Prognostic cell-based assay predicts acute cellular rejection in pre- and post-transplant testing...
Chethan Ashokkumar1, Rafia Khan1, Kyle A. Soltys1,Geoffrey Bond1, George V. Mazariegos1,
Brandon W. Higgs1, Rakesh Sindhi1
INSTITUTIONS (ALL): 1. Children's Hospital of Pgh of UPMC, Pittsburgh, PA, United States.
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- - Assess disease risk for several immunological disorders.
- - Predict the success of a drug for a specific patient.
- - Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA